2 recruiting, 1 active not recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Oryzon Genomics S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Iadademstat + SBRT With Atezo in ES-SCLC Iadademstat, Atezolizumab, SBRT - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | Recruiting | Yale University | 15 | 2026-01-20 | 2026-09-14 |
| Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 30 | 2024-08-22 | 2026-06-30 |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) Iadademstat, Gilteritinib Oral Tablet - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Active not recruiting | Oryzon Genomics S.A. | 50 | 2022-11-14 | 2026-08-24 |
Leukemia, Myeloid, Acute (2) · GATA2 Deficiency (1) · Recurrence (1)
iadademstat (3) · Azacitidine (1) · Biopsy (1) · Specimen Handling (1) · atezolizumab (1) · gilteritinib (1) · venetoclax (1)
United States (3)
Annie Chiang, MD (1) · Curtis A Lachowiez (1)